Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes mellitus:

A nationwide population-based study

Pai-Feng Hsu, M.D.[a,b,c,d], Shih-Hsien Sung, M.D.[b,c,d], Hao-Min Cheng, M.D.[b,h, f], Jong -Shiuan Yeh, M.D.[e,i], Wen-Ling Liu M.S.[g] , Wan-Leong Chan, M.D.[a,d] Chen-Huan Chen, M.D.[b,c] Pesus Chou, Dr.P.H.[c], Shao-Yuan Chuang, Ph.D.[g]

[a]Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan; [b]Department of Medicine and [c]Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taiwan; [d]Cardiology Division, Internal Medicine Department; [e]Taipei Medical University Wan-Fang Hospital, Taipei, Taiwan; [f]Department of Medical Research and Education; [g]National Health Research Institutes, Miaoli, Taiwan; [h]The Joanna Briggs Institute, Faculty of Health Sciences, The University of Adelaide, Adelaide, Australia; [i]The Skirball Center for Cardiovascular Research, Cardiovascular Research Foundation, Orangeburg, NY, USA

*Shin-Hsien Sung is a co-first author

running title: hypoglycemia and cardiovascular events

Total word count: 3057

Word count of abstract: 244

Total number of figures: 2

Total number of tables: 2

Corresponding author: Shao-Yuan Chuang

National Health Research Institutes, Miaoli, Taiwan

Tel: (037) 246166 #36340

Fax: (037) 586261

E-mail: chuangsy@nhri.org.tw

Abstract

Objective

Hypoglycemia is associated with serious health outcomes for patients treated for diabetes mellitus. However, the outcome of outpatients with type 2 diabetes who have experienced hypoglycemia episodes is largely unknown.

Research Design and Methods

The study population, derived from the National Health Insurance Research Database released by the Taiwan National Health Research Institutes during 1998–2009, comprised 77,611 newly diagnosed patients with type 2 diabetes mellitus. We designed a prospective study consisting of randomly selected, hypoglycemic type 2 diabetes patients and matched type 2 diabetes patients without hypoglycemia. We investigated the relationships of hypoglycemia with total mortality and cardiovascular events including stroke, coronary heart disease, cardiovascular diseases (CVD), and all-cause hospitalization.

Results

There were 1,844 hypoglycemic events (500 inpatients and 1,344 outpatients) among the 77,611 patients. Both mild (outpatient) and severe (inpatient) hypoglycemia cases had a higher percentage of comorbidities, including hypertension, renal diseases, cancer, stroke, and heart disease. In multivariate Cox regression

models, including diabetes treatment adjustment, diabetes patients with hypoglycemia had a significantly higher risk of cardiovascular events during clinical treatment periods. After constructing a model adjusted with propensity scores, mild and severe hypoglycemia still demonstrated higher hazard ratios for CVD (2.09; 95% confidence interval 1.63–2.67), all-cause hospitalization (2.51, 2.00–3.16), and total mortality (2.48; 1.41–4.38).

Conclusions

Symptomatic hypoglycemia, whether clinically mild or severe, is associated with an increased risk of cardiovascular events, all-cause hospitalization, and all-cause mortality. More attention may be needed for diabetes patients with hypoglycemic episodes.

Hypoglycemia is a major side effect of glucose-lowering therapy in both type 1 and type 2 diabetes mellitus patients. Patients with type 2 diabetes are believed to usually have less-frequent hypoglycemia episodes than type 1 patients (1). Prodromal symptoms of hypoglycemia, including tremor, diaphoresis, tachycardia, and anxiety, are sometimes noticed by the patient, and consequently severe complications can be avoided. If left untreated, however, neuroglycopenia may develop, resulting in neurological damage (2, 3).

Hypoglycemia has also been associated with adverse cardiovascular events in type 2 diabetes patients beyond hypoglycemic episodes themselves (4). The surge of sympathetic activity during hypoglycemic episodes has been suggested to be the underlying mechanism, leading to destabilization of atherosclerotic plaques (5), increased arrhythmia owing to increased corrected QT interval (6), and induction of cardiac and cerebral ischemia. Studies including epidemiological cohort studies and clinical trials (7, 8, 9, 10) have already suggested that hypoglycemia is indeed a risk factor for cardiovascular outcomes. However, some patients in these studies had comorbidities on admission, such as unstable angina and acute myocardial infarction (11, 12, 13, 14). Recently, the ADVANCE study suggested that hypoglycemia is associated with increased risks of a range of adverse clinical outcomes and is

considered to be a marker for vulnerability to such events for type 2 diabetes patients (15).

Whether hypoglycemia is a risk factor or a marker, it is important to evaluate the possible correlates to both hypoglycemia and serious health conditions, including hepatic disease, malignancy, renal disease, and use of various medications. Furthermore, in real-world clinical practice it is intriguing to identify hypoglycemic events based solely on symptoms or a physician's diagnosis rather than on glucose levels, as most previous studies have done. Moreover, patient selection bias, especially the Berkson's bias, in hospital-based observational or case-control studies probably confounds and casts doubt on the associations between hypoglycemia and clinical outcomes. Lastly, the clinical impact of mild, self-reported hypoglycemic episodes is largely unknown. We therefore conducted this nationwide, random sampling, cohort study of type 2 diabetes patients to characterize their comorbidities, evaluate the influences of mild and severe hypoglycemia, and their outcomes.

RESEARCH DESIGN AND METHODS

Study population

In Taiwan, National Health Insurance is a single-payer program that has operated since 1995, covering 98% of the population. The database includes patient demographics, diagnosis, and prescriptions in the hospital and in outpatient claims. Currently, the National Health Research Institutes (NHRI) is in charge of the National Health Insurance Research Database (NHIRD) in Miaoli, Taiwan (available at: www.nhri.org.tw/nhird/), and the complete National Health Insurance claims database along with several dozen extracted datasets are available to researchers. A nationally representative group of one million individuals was randomly selected from all insured persons in NHIRD, which is also one of the largest nationwide population-based databases in the world. All selected insured persons' medical records from 1996 to 2009 were included in the dataset. For research purposes, the information on all persons was managed with a double scrambling protocol. The original identification number was encrypted to protect privacy while maintaining consistency. Therefore, it was possible to follow patients by linking claims belonging to the same patient within the NHIRD datasets. Since the National Health Insurance was initiated from 1996, the claim data was not totally comepleted. We included data from individuals who were enrolled between January 1, 1997 and December 31, 2009.

Study design

We designed a cohort of type 2 diabetes patients from the one million patients in the nationally representative sample dataset. We excluded patients with diabetes medical records before December 31, 1997. A total of 77,611 new diabetes patients were identified as having received a diagnosis of diabetes more than three times [ICD-9CM: 250.XXX] from 1998 to 2009. Among them, 500 diabetes patients with hypoglycemia [ICD-9-CM: 251.2X] were identified from the hospital claims dataset (defined as severe hypoglycemia), and 1,344 diabetes patients with hypoglycemia were identified from the outpatient claims dataset (defined as mild hypoglycemia).

Further, we also designed a cohort consisting of hypoglycemic type 2 diabetes patients and randomly selected and matched them with type 2 diabetes patients without hypoglycemia. To control for the confounding effects of age, gender, and diabetes duration, we constructed a matched variable containing the age at hypoglycemia onset, gender, and diabetes duration for each patient with hypoglycemia. The diabetes duration was calculated from the first diagnosis date to the date of hypoglycemia onset.

Then we used SAS MACRO to identify hypoglycemic diabetes patients with the same matched variable and randomly selected one to four non-hypoglycemic diabetes

cases from those with the same match variables. Finally, we randomly selected 7,376 diabetes patients without hypoglycemia by matching age of hypoglycemia onset, gender, and diabetes duration. Each matched pair had the same initial date (hypoglycemia onset date) signaling the commencement of follow-up (Figure 1).

Definition of variables

Patients with a diagnosis of diabetes were defined as those with three outpatient claims with ICD-9-CM code 250. All confounding variables were defined according to the diagnosis before the index date in hypoglycemic and non-hypoglycemic patients. Hypertension was defined as two outpatient claims with ICD-9-CM code 401–405. Dyslipidemia was defined as two outpatient claims with ICD-9-CM code 272. Atrial fibrillation was defined as two outpatient claims with ICD-9-CM 427.3X. Liver cirrhosis was defined as two outpatient visits with ICD-9-CM between 571.2X or 571.5X. Renal disease was defined as two outpatient visits with ICD-9-CM between 580 and 589. Mental diseases were defined as two outpatient visits with ICD-9-CM between 290 and 319. The socioeconomic status was defined according to the insured's salary (median: 16,500 new Taiwan dollars). Compliance with diabetes treatment was measured by proportion of days covered of treatment (PDC) (16). Sufficient compliance of treatment for diabetes was defined PDC ≥ 80% (17).

Cancer, stroke, coronary heart disease (CHD), and cardiovascular disease (CVD) were also identified from the hospital claim dataset. Cancer diseases were defined by ICD-9-CM codes between 140 and 239. Stroke was defined by ICD-9CM codes 430–438. CVD was defined by ICD-9-CM codes 390–459.

Death status was ascertained according to (1) the discharge reasons with death or critically ill discharge, or (2) quit insurance with death.

Statistical methods

The different groups were compared using the unpaired Student's *t*-test for parametric continuous data and the chi-square test for categorical data. We investigated the relationship between hypoglycemia and cardiovascular events. Survival time was calculated from the date of hypoglycemia diagnosis for each data pair to the onset date of the event (stroke, CHD, CVD, or any cause for hospitalization), death, or end of study (December 31, 2009). The Kaplan-Meier method was used to estimate the survival curves, and the log-rank test was used to test the homogeneity between survival curves. Hazard ratio (HR) and the 95% confidence interval (CI) for the Cox proportional hazard model were used to evaluate the association between hypoglycemia and cardiovascular events. We also performed a propensity score analysis to evaluate the association between hypoglycemia and cardiovascular events, hospitalization, and total mortality. All statistical analyses were

performed using Statistical Package for SAS 9.2 (SAS Institute, Inc, Cary, NC).

RESULTS

Incidence of hypoglycemia

There were 1,844 hypoglycemic events (500 in inpatients and 1,344 in outpatients) among 77,611 new type 2 diabetes patients from 1998–2009. The incidence of hypoglycemia was 2.38% (1,844/77,611). Women had a higher risk of hypoglycemia than men (1.34% vs. 1.04%, $p < 0.0001$).

Characteristics of hypoglycemic and matched non-hypoglycemic type 2 diabetes patients (Table 1)

Hypertension, atrial fibrillation, liver cirrhosis, renal disease, mental disease, history of cancer disease, stroke, and heart disease were positively associated with hypoglycemia risk. The percentage of insulin and sulfonylureas usage and good compliance with diabetes medications were also higher in both mild and severe hypoglycemia cases. However, social economic status did not differ significantly between hypoglycemic and non-hypoglycemic cases. Owing to the matched conditions, the variables age, gender, and duration of diabetes did not differ between hypoglycemic and non-hypoglycemic patients (Table 1). In both mild and severe hypoglycemia matched case controls, comorbidities independently associated with hypoglycemia were: hypertension (HR = 1.75; 95% CI: 1.57–1.96), atrial fibrillation

(1.96; 1.24–3.11), liver cirrhosis (1.71; 1.17–2.48), renal disease (3.26; 2.76–3.86), mental disease (1.50; 1.30–1.73), cancer (2.73; 2.12–3.50), stroke (2.84; 2.31–3.48), and coronary heart disease (2.04; 1.65–2.51).

Total mortality and incidence of stroke, CHD, and cardiovascular events in hypoglycemic diabetes patients

During the follow-up period, 1,187 diabetes patients developed stroke, 1,164 developed CHD, 3,515 developed cardiovascular events, and 773 died before the end of the study.

Patients with hypoglycemia had a significantly higher risk of cardiovascular events during the clinical treatment periods (Figure 2). Compared with patients without hypoglycemia, those with hypoglycemia (both inpatient and outpatient claims datasets) had a higher hospitalization rate for stroke (27.97 vs. 69.05, 71.73 respectively, per 1000 person-years; both $p < 0.0001$), CHD (27.96 vs.65.51, 65.77 respectively, per 1000 person-years, both $p < 0.0001$), CVD hospitalization (106.00 vs.323.36, 325.79 respectively, per 1000 person-years, both $p < 0.0001$), and total mortality (14.30 vs.41.04, 52.28 respectively, per 1000 person-years, all comparisons, $p < 0.0001$). Both inpatients and outpatients with hypoglycemia carried a more than 2-fold higher relative risk of stroke (HR = 2.55; 95% CI = 2.24–2.90), CHD events

(2.35; 2.06–2.68), CVD (3.19; 2.94–3.47), and total mortality (3.49; 3.01–4.05).

Table 2 shows the independent risk factors for stroke events, CHD events, cardiovascular events, and total mortality. In the multivariate Cox regression model, both mild and severe hypoglycemia events showed increased HRs for stroke, CHD, and all cardiovascular events after adjusting for other important co-morbidities.

Furthermore, we also estimated the association between hypoglycemia and cardiovascular events, hospitalization, and total mortality for patients with insulin treatment (n = 1,068) and sulphonylurea treatment (n = 4,817). The HRs (95% CI) for mild and severe hypoglycemia were as follows: 2.57 (0.73–9.09) and 1.44 (0.40–5.17), respectively, for stroke; 2.06 (0.76–5.57) and 2.10 (0.45–9.77), respectively, for CHD; 2.21 (1.39–3.53) and 1.48 (0.69–3.19), respectively, for CVD; and 1.94 (0.79–4.76) and 2.67 (0.68–10.45), respectively, for total mortality for patients with insulin treatment. Hypoglycemia was significantly and positively correlated with cardiovascular events and mortality for patients receiving sulphonylurea treatment. The HRs for mild and severe hypoglycemia were as follows: 1.82 (1.41–2.34) and 1.32 (0.96–1.82), respectively, for stroke; 1.88 (1.47–2.42) and 1.35 (0.99–1.85), respectively, for CHD; 2.32 (1.98–2.70) and 1.96 (1.59–2.43), respectively, for CVD; and 2.97 (2.22–3.97) and 2.24 (1.53–3.27), respectively, for total mortality. As shown in Table 2, the results were similar for patients who had good medication compliance,

as defined by PDC.

Hypoglycemia and hospitalization

The hospitalization rate was 73.1% (1,348/1,844) among hypoglycemic diabetes patients during the observation period. Hypoglycemic patients had a 3.54-fold higher risk of being hospitalized (CI = 3.27–3.82). Further, the first-year hospitalized rate was 53.1% (714/1344) for patients with mild hypoglycemia and 63.4% (317/500) for those with severe hypoglycemia (Figure 2B). Moreover, 76.5% (n = 1,031/1,384) of hospitalization events occurred during the first year after hypoglycemia onset. The reason for admission of these hypoglycemic patients in the first year included CVD (ICD: 390–459, 22.0%), diabetes (ICD-9-CM: 250, 18.5%), genitourinary disease (ICD-9-CM: 580–629, 10.7%), and digestive disease (ICD-9-CM: 520–527, 8.7%).

Propensity score analysis

Propensity score analysis was conducted to evaluate the association between hypoglycemia, including both mild and severe cases, and hospitalization for cardiovascular events and total mortality. The distributions of potential confounding variables (Supplemental Table S1) did not differ significantly between diabetes mellitus patients with or without hypoglycemia in the propensity score matched data. Hypoglycemic patients had about a 2-fold higher relative risk of cardiovascular events

(HR = 2.09; 95% CI = 1.63–2.67), hospitalization (2.51; 2.00–3.16), and total death (2.48; 1.41–4.38) in the propensity matched dataset.

CONCLUSIONS

The major findings of this study suggest that hypoglycemia episodes, both mild and severe, are strongly associated with subsequent major cardiovascular events including stroke, CHD, and CVD hospitalization in outpatient-treated type 2 diabetes patients. Furthermore, higher all-cause mortality was associated with these hypoglycemic events. Diabetes patients who are vulnerable to hypoglycemia have more comorbidities including hypertension, liver cirrhosis, renal disease, mental disease, cancer, and previous stroke or heart diseases. Medications, including insulin and sulfonylurea, are also important factors that impact clinical events related to hypoglycemia. Once outpatient-treated diabetes patients have hypoglycemic episodes, cardiovascular and hospitalization events occur most frequently in the first year after the hypoglycemic event regardless of whether the hypoglycemia was mild or severe.

The incidence of clinical hypoglycemic events, including both mild and severe types, was lower in our study than in previous clinical trials such as ACCORD (12) and community epidemiological studies in other countries such as the United Kingdom (19, 20). A lower proportion of patients with hypoglycemia has been reported in Asian Pacific countries and Taiwan (18), which may be explained by more

conservative treatment strategies in Taiwanese clinical diabetes control (21).

In recent years, intensive glucose control strategies for long-duration type 2 diabetes patients have been intensively studied, including in the VADT (13), ADVANCE (14), and ACCORD trials (12). These trials did not consistently support strategies to improve reductions in cardiovascular events or mortality. Excessive mortality in intensive glucose control groups has led to debate regarding hypoglycemia-related adverse outcomes. However, a post-hoc analysis of the data from the ACCORD trial suggests that the excess mortality in the intensively treated group cannot be directly explained by the more frequent episodes of hypoglycemia in this group of patients (22). The post-hoc analysis of the data from the ADVANCE study also recently suggests that severe hypoglycemia is strongly associated with increased risk of adverse clinical outcomes, including macrovascular and microvascular changes and death from cardiovascular events. Because there is no relationship between repeated hypoglycemia episodes and adverse outcomes, the authors conclude that hypoglycemia is a likely marker of vulnerability to such events (15).

Although some previous studies have shown that hypoglycemia is a risk factor for future cardiovascular events, these analyses were almost all based on patients recruited during hospitalization (7, 8). Most of the epidemiological analyses were

from clinical trials related to acute myocardial infarction, including the DIGAMI-2 and OASIS-6 trials (9, 10). In contrast, our study population was recruited from real-world outpatient clinical practice, and our results suggest that clinically driven hypoglycemia in diabetes may increase adverse cardiovascular outcomes and hospitalization from any cause by about 2-fold. Even after propensity score–adjusted analysis, hypoglycemia still carries about 2.0–2.5 times the risk for CVD events, all-cause hospitalization, and all-cause mortality. Our result was similar to a retrospective epidemiological analysis of the ACCORD study, which showed an HR of ~2.87 for all-cause mortality with severe versus no severe episodes of hypoglycemia in a standard treatment group (22). These observations suggest that hypoglycemia occurs as a consequence of intensive therapeutic intervention and has a different relationship with serious cardiovascular outcomes or death than spontaneous hypoglycemia or episodes that occur as part of routine diabetes management (4).

Furthermore, many previous studies have suggested that hypoglycemia is a risk factor for serious health outcomes. Combined with evidence that therapies promoting hypoglycemia do not increase these outcomes, hypoglycemia is more likely to be associated with other risk factors for these outcomes rather than causally related to them (22). On the other hand, studies have demonstrated that hypoglycemia events in general-ward patients have a dose-dependent relationship with the length of hospital

stay and in-hospital mortality (23). Hypoglycemia may result in poor outcomes for diabetes patients by leading to falls, seizures, or non-medical death. This was not found in our study, as the most frequent causes of hospitalization were for CVD, diabetes, genitourinary disease, and digestive disease. Our results also suggest that hypoglycemia may be a marker for disease severity in these routinely treated diabetes patients. Diabetes patients who experienced hypoglycemic episodes were more likely to be on insulin and sulphonylurea and have better treatment compliance. This may indirectly indicate a greater severity of diabetes for patients prone to hypoglycemic events. However, data for blood sugar or HbA1c levels are not present in this type of administration database, and so these parameters could not be considered.

Some papers have studied the possible mechanics of symptomatic hypoglycemia and suggested that hypoglycemia may predispose patients to adverse cardiovascular outcomes. Hypoglycemia may be associated with elevated sympathetic activity and release of catecholamines, thereby promoting destabilization of atherosclerotic plaques (24). Hemodynamic changes with increased myocardial work, hypoglycemia-induced increase in platelet aggregation, and platelet activity may also precipitate cardiac or cerebral ischemic insults in high-risk type 2 diabetes patients (25, 26). Additionally, one study revealed a higher frequency of ischemic electrocardiogram changes or a nocturnal increase in the corrected QT interval

accompanied by rhythm disturbance when hypoglycemia develops (27).

In this nationwide cohort study, we also found that diabetes patients who are prone to hypoglycemia episodes are more likely to have comorbidities such as hypertension, renal disease, heart disease, stroke, and cancer history with borderline atrial fibrillation and liver disease. Previous studies also support this association of severe hypoglycemia with older age, longer duration of diabetes, higher creatinine level, use of two or more oral glucose-lowering agents, and assignment to intensive glucose control (28). Although our study patients were matched for age, gender, and diabetes duration, this trend of associations was still evident.

Limitations

First, neither the educational status of individuals nor information about personal habits such as smoking, extent of physical activity, body mass index, or the exact condition of glycemic control were available from the NHIRD. Second, this study was conducted with data from NHIRD, and the diagnosis was assumed to have been confirmed clinically by the individual physician in charge. The occurrence of mild or severe hypoglycemia was only confirmed by the outpatient or inpatient record of clinical hypoglycemia, and patient glucose levels were not recorded. By using a case-control study design, we hoped to minimize the impact of selection, misclassification, and diagnostic bias. Third, the study population consisted of

Taiwanese patients who were of Chinese descent, and thus, the results may not be easily generalized to other populations.

In conclusion, symptomatic hypoglycemia, both clinically mild and severe, is associated with an increased risk for cardiovascular events, all-cause hospitalization, and all-cause mortality. Adverse events after hypoglycemia occurred most frequently in the first year. Clinically, more attention may be needed for diabetes patients with hypoglycemic episodes.

Acknowledgments

This study was conducted in part using data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes. No potential conflicts of interest relevant to this article are reported.

Author contributions as follows: Manuscript study design: P-F Hsu, S-H Sung, and S-Y Chuang; data acquisition: P-F Hsu and S-Y Chuang; data analysis: W-L Liu and S-Y Chuang; results interpretation: P-F Hsu, S-H Sung, H-M Cheng, J-S Yeh, W-L Chan, C-H Chen, Pesus Chou, and S-Y Chuang; manuscript drafting: P-F Hsu,

S-H Sung, and S-Y Chuang. S-Y Chuang takes responsibility for the contents of the article.

Grant support: This work was supported in part by an intramural grant from the Taipei Veterans General Hospital (grant no. V100B-031) and a grant from the National Health Research Institutes (grant no. PH-100-PP-55 and PH-101-PP-24).

References

1. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147
2. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24:87–92
3. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract. 2004;65 Suppl 1:S47–52
4. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011;123:342–348
5. Hilsted J, Bonde-Petersen F, Nørgaard MB, et al. Haemodynamic changes in insulin-induced hypoglycaemia in normal man. Diabetologia. 1984;26:328–332
6. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia. 2009;52:42–45
7. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005; 26:1255-1261.
8. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients

hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008; 117:1018-1027.

9. Malmberg K, Rydén L, Wedel H,et al. DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005; 26:650-661.
10. Goyal A, Mehta SR, Díaz R,et al. Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation. 2009; 120:2429-2437.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
12. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-2559.
13. Duckworth W, Abraira C, Moritz T,et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129-139.

14. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572.

15. Zoungas S, Patel A, Chalmers J,et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363:1410-1418.

16. Calculating Medication Compliance, Adherence, and Persistence in adminstrative pharmacy Claims Databases.[article online], 2008 available from http://www.wuss.org/proceedings08/08WUSS%20Proceedings/papers/anl/anl09. assessed 12 July 2012.

17. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 24-31:455-461.

18. Wang CY, Lin CL, Huang TS, et al. Inertia on hypoglycemia: Highlight from a Taiwan subgroup analysis of Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Res Clin Pract. 2012 Jun 14.

19. Donnelly LA, Morris AD, Frier BM,et al. DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005; 22:749-755.

20. Gürlek A, Erbaş T, Gedik O. Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes. 1999; 107:220-4.

21. Tai TY, Chuang LM, Tsai ST, Huang BY; Diabcare (Taiwan) Study Group. Treatment of type 2 diabetes mellitus in a primary care setting in Taiwan: comparison with secondary/tertiary care. J Formos Med Assoc. 2006; 105:105-117.

22. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b4909.

23. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153-1157.

24. DeFronzo RA, Hendler R, Christensen N. Stimulation of counterregulatory hormonal responses in diabetic man by a fall in glucose concentration. Diabetes. 1980; 29:125-131.

25. Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet

function. J Clin Pathol. 1979; 32:434-438.

26. Frier BM, Corrall RJ, Davidson NM, Webber RG, Dewar A, French EB. Peripheral blood cell changes in response to acute hypoglycaemia in man. Eur J Clin Invest. 1983; 13:33-39.

27. Robinson RT, Harris ND, Ireland RH, Macdonald IA, Heller SR. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with Type 1 diabetes. Diabetologia. 2004; 47:312-315.

28. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.

Table 1 Characteristics of diabetes patients with hypoglycemia and matched diabetes patients without hypoglycemia

	Severe hypoglycemia (n = 500)		No hypoglycemia (n = 2,000)		p-value	Mild hypoglycemia (n = 1,344)		No hypoglycemia (n = 5,376)		p-value
Age, years	65.2 ± 9.2		65.2 ± 9.2		1.0000	62.6 ± 9.6		62.6 ± 9.6		1.0000
Males	233	46.60%	932	46.60%	1.0000	573	42.63%	2292	42.63%	1.0000
Duration, yrs	3.75 ± 2.8		3.75 ± 2.8		1.0000	5.41 ± 3.1		5.41 ± 3.1		1.0000
Hypertension	318	63.60%	1023	51.15%	<0.0001	895	66.59%	2600	48.36%	<0.0001
Atrial fibrillation	6	1.20%	14	0.70%	0.2616	27	2.01%	45	0.84%	0.0002
Dyslipidemia	85	17.00%	433	21.65%	0.0218	408	30.36%	1351	25.13%	<0.0001
Liver cirrhosis	15	3.00%	26	1.30%	0.0074	32	2.38%	78	1.45%	0.0162
Renal disease	87	17.40%	103	5.15%	<0.0001	226	16.82%	286	5.32%	<0.0001
Mental disease	107	21.40%	250	12.50%	<0.0001	262	19.49%	688	12.80%	<0.0001

Cancer	40	8.00%	48	2.40%	<0.0001	84	6.25%	130	2.42%	<0.0001
Stroke	75	15.00%	80	4.00%	<0.0001	150	11.16%	176	3.27%	<0.0001
Heart disease	66	13.20%	72	3.60%	<0.0001	132	9.82%	203	3.78%	<0.0001
High social economic status	214	42.80%	937	46.85%	0.1041	700	52.08%	2854	53.09%	0.5094
Good compliance	142	28.40%	529	26.45%	0.3788	302	22.47%	866	16.11%	<0.0001
Insulin	121	24.20%	87	4.35%	<0.0001	460	34.23%	400	7.44%	<0.0001
Sulfonylureas	339	67.80%	1099	54.95%	<0.0001	912	67.86%	2467	45.89%	<0.0001
Other drugs	307	61.40%	940	47.00%	<0.0001	894	66.52%	2404	44.72%	<0.0001

Other drugs: Other orally administered diabetes medications.

Good compliance of treatment: Proportion of days covered (PDC) > 80%.

High social economic status: salary of the insured more than the median (16,500 new Taiwan dollars).

Data shown are mean ± standard deviation or number of patients and percent.

Table 2. Association between hypoglycemia and hospitalization due to stroke, coronary heart disease, and cardiovascular causes in the multivariate model.

	Stroke		CHD		CVD		Death	
Variables	HR	95% CIs	HR	95% CIs	HR	95% CIs	HR	95% CIs
Hypertension, Yes vs. No	1.61	1.39–1.86	1.53	1.31–1.78	1.95	1.78–2.13	1.28	1.07–1.54
Atrial fibrillation, Yes vs. No	1.26	0.63–2.52	1.49	0.79–2.82	1.67	1.12–2.48	0.93	0.43–2.01
Dyslipidemia, Yes vs. No	0.88	0.75–1.05	1.33	1.12–1.57	1.01	0.91–1.11	0.73	0.59–0.91
Liver cirrhosis, Yes vs. No.	0.60	0.31–1.16	0.60	0.30–1.19	1.49	1.09–2.05	2.28	1.32–3.93
Renal disease, Yes vs. No	1.26	0.97–1.63	1.49	1.17–1.91	1.79	1.54–2.08	2.01	1.52–2.65
Mental disease, Yes vs. No	1.12	0.93–1.35	1.04	0.86–1.26	1.03	0.92–1.16	1.12	0.83–1.43
Previous cancer, Yes vs. No	0.66	0.43–1.01	0.58	0.36–0.92	1.03	0.81–1.31	2.03	1.36–3.02
Previous stroke, Yes vs. No	4.26	3.35–5.42	0.76	0.56–1.03	1.42	1.19–1.69	1.26	0.91–1.74
Heart disease, Yes vs. No	1.13	0.85–1.52	4.73	3.68–6.08	1.96	1.64–2.34	1.30	0.94–1.79
High social economic status	0.94	0.81–1.09	0.91	0.78–1.05	0.96	0.87–1.04	0.58	0.48–0.71

Good compliance	1.15	0.97–1.36	1.06	0.90–1.25	1.14	1.03–1.26	1.21	0.98–1.49
Insulin	1.63	1.29–2.07	1.54	1.21–1.95	1.74	1.51–2.01	1.74	1.34–2.27
Sulfonylureas	1.17	1.00–1.37	1.30	1.11–1.53	1.34	1.22–1.47	1.38	1.14–1.67
Mild hypoglycemia	1.92	1.60–2.31	1.76	1.46–2.13	2.21	1.98–2.47	2.70	2.19–3.33
Severe hypoglycemia	1.64	1.29–2.07	1.63	1.28–2.08	2.26	1.93–2.65	2.18	1.66–2.88

Other drugs: Other oral diabetes medications.

Good compliance of treatment: Proportion of days covered (PDC) > 80%.

High social economic status: salary of the insured more than the median (16,500 new Taiwan dollars)

Figure Legends

Figure 1. Flow chart of study population

Figure 2. Association between hypoglycemia and hospitalization. (A) Survival curves for patients with hypoglycemia and hospitalization. (B) The hospitalization rate (n = 1,348) during the follow-up period was 53.1% (n = 714/1,344) for mild hypoglycemia and 63.4% (n = 317/500) for severe and occurred in the first year.



Figure 1. Flow chart of study population



Figure 2. Association between hypoglycemia and hospitalization. (A) Survival curves of hypoglycemia and hospitalization. (B) The hospitalized rates (n=1348) during the follow-up period, was 53.1% (714/1344) for mild and 63.4% (n=317/500) for severe occurred in the first year, respectively.